Drugging the undruggable RAS: Mission Possible?
Open accessThe DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Abstract
Despite more than three decades of intensive effort, no effective pharmacological inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'. However, recent data from the laboratory and the clinic have renewed our hope for the development of RAS-inhibitory molecules. In this Review, we summarize the progress and the promise of five key approaches. Firstly, we focus on the prospects of using direct inhibitors of RAS. Secondly, we address the issue of whether blocking RAS membrane association is a viable approach. Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favourable current approach. Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise. Finally, RAS-mediated changes in cell metabolism have recently been described and we discuss whether these changes could be exploited for new therapeutic directions. We conclude with perspectives on how additional complexities, which are not yet fully understood, may affect each of these approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS has historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable pockets within the mutant isoforms.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of highly selective and potent inhibitors have been developed against kinases in the Ras signaling network particularly those in the MAPK and PI3K/mTOR pathways (9, 12).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For more than 40 years, KRAS mutation has been considered “undruggable” [16, 17].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For many proteins known to be involved in driving diseases, such as KRAS in many cancers, conventional drug development strategies often aimed at developing inhibitors have failed [118, 119].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [119]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Research works printed but not linked: 1
- Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642–655 (2012). · DOI · Paper page
Cited by
Items 201–300 of 1,007
Improving prospects for targeting RAS
Singh, H., Longo, D. L., & Chabner, B. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1052 · Cited by 107
Ozkan-Dagliyan, I., Diehl, J. N., George, S. D., Schaefer, A., Papke, B., Klotz-Noack, K., Waters, A. M., Goodwin, C. M., Gautam, P., Pierobon, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107764 · Cited by 106
“%) in PDAC (Cox et al., 2014).”
BackgroundSelf-citationSalem, M. E., El-Refai, S. M., Sha, W., Puccini, A., Grothey, A., George, T. J., Hwang, J. J., O'Neil, B., Barrett, A. S., Kadakia, K. C., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00245 · Cited by 101
“More than three decades of efforts to target KRAS downstream signaling pathways in KRAS-mutated cancers have largely been ineffective.(4) The recent development of KRAS-selective inhibitors of GTP binding—locking KRAS in an inactive state(5,6)—established a foundation for the development of inhibitors suitable for cli…”
BackgroundK-Ras protein as a drug target
McCormick, F. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1382-7 · Cited by 105
“The roles of distinct Ras effectors in normal cells and in cancer have been discussed recently elsewhere [17, 18].”
BackgroundSuzuki, S., Yonesaka, K., Teramura, T., Takehara, T., Kato, R., Sakai, H., Haratani, K., Tanizaki, J., Kawakami, H., Hayashi, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0856 · Cited by 105
“KRAS mutations are observed most frequently, occurring in 85% of all RAS-mutated cancers (8).”
BackgroundWu, K., Lam, N. Y. S., Strassfeld, D. A., Fan, Z., Qiao, J. X., Liu, T., Stamos, D. P., & Yu, J. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202400509 · Cited by 106
Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation
Kano, Y., Gebregiworgis, T., Marshall, C. B., Radulovich, N., Poon, B. P. K., St-Germain, J., Cook, J. D., Valencia-Sama, I., Grant, B. M. M., Herrera, S. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08115-8 · Cited by 103
Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange
Guillard, S., Kolasinska-Zwierz, P., Debreczeni, J., Breed, J., Zhang, J., Bery, N., Marwood, R., Tart, J., Overman, R., Stocki, P., et al. (2017) · Nature Communications · doi:10.1038/ncomms16111 · Cited by 102
A second chance for telomerase reverse transcriptase in anticancer immunotherapy
Zanetti, M. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.67 · Cited by 109
Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers
Seguin, L., Camargo, M. F., Wettersten, H. I., Kato, S., Desgrosellier, J. S., von Schalscha, T., Elliott, K. C., Cosset, E., Lesperance, J., Weis, S. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0539 · Cited by 102
“Despite intense efforts to target KRAS or its key effectors, compensatory pathways have limited the ability of such agents to achieve clinical impact [26, 27].”
BackgroundLinnane, E., Davey, P., Zhang, P., Puri, S., Edbrooke, M., Chiarparin, E., Revenko, A. S., Macleod, A. R., Norman, J. C., & Ross, S. J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz214 · Cited by 101
“(A and B) Colon, pancreatic and NSCLC cancer cells were treated with a dose range of AZD4785 for 72 h and RT-qPCR used to assess KRAS mRNA levels.”
BackgroundInfluentialFerreira, A. I., Pereira, F. D. S., Reis, C. A., Oliveira, M. J., Sousa, M. J., & Preto, A. (2022) · Cells · doi:10.3390/cells11142183 · Cited by 123
“In addition, the direct inhibition of KRAS has not presented successful results and efforts have been made to focus on targeting their downstream signaling proteins [49].”
BackgroundSOS GEFs in health and disease
Baltanás, F. C., Zarich, N., Rojas-Cabañeros, J. M., & Santos, E. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188445 · Cited by 100
Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics
Chen, H., Smaill, J. B., Liu, T., Ding, K., & Lu, X. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01312 · Cited by 93
Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer
Liu, H., Liang, Z., Zhou, C., Zeng, Z., Wang, F., Hu, T., He, X., Wu, X., Wu, X., & Lan, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00534-2 · Cited by 112
SIRT2 and lysine fatty acylation regulate the transforming activity of K-Ras4a
Jing, H., Zhang, X., Wisner, S., Chen, X., Spiegelman, N. A., Linder, M. E., & Lin, H. (2017) · eLife · doi:10.7554/elife.32436 · Cited by 102
“KRAS mutations, which affects both K-Ras4a and K-Ras4b, occur most frequently, accounting for 86% of RASdriven cancers (Cox et al., 2014).”
BackgroundClinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
Patel, H., Okamura, R., Fanta, P. T., Patel, C., Lanman, R. B., Raymond, V. M., Kato, S., & Kurzrock, R. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0824-4 · Cited by 105
The molecular genetics of RASopathies : An update on novel disease genes and new disorders
Tartaglia, M., Aoki, Y., & Gelb, B. D. (2022) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.32012 · Cited by 116
Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment
Polireddy, K., & Chen, Q. (2016) · Journal of Cancer · doi:10.7150/jca.14922 · Cited by 119
“Pharmacological agents targeting K-Ras for pancreatic cancer is currently an active area of research (224).”
BackgroundTargeting mutant KRAS with CRISPR-Cas9 controls tumor growth
Kim, W., Lee, S., Kim, H. S., Song, M., Cha, Y. H., Kim, Y.-H., Shin, J., Lee, E.-S., Joo, Y., Song, J. J., et al. (2018) · Genome Research · doi:10.1101/gr.223891.117 · Cited by 97
“Activating mutations in KRAS play potent roles in cancer initiation, propagation, and maintenance, representing important therapeutic targets (Cox et al. 2014).”
BackgroundKRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe
Bery, N., Legg, S., Debreczeni, J., Breed, J., Embrey, K., Stubbs, C., Kolasinska-Zwierz, P., Barrett, N., Marwood, R., Watson, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10419-2 · Cited by 97
Targeting KRAS in pancreatic cancer
Stickler, S., RATH, B., & Hamilton, G. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.045356 · Cited by 118
“Although KRAS mutations are detectable in a high proportion of PDACs, almost in half of colorectal adenocarcinomas (CRC) and in approximately 30% of lung adenocarcinomas, higher response rates for KRAS-targeted therapy are so far restricted to lung cancer [18].”
Consensus, debate, and prospective on pancreatic cancer treatments
Wang, J., Yang, J., Narang, A. K., He, J., Wolfgang, C. L., Li, K., & Zheng, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01613-x · Cited by 109
KRAS G12C–Mutant Non–Small Cell Lung Cancer
Veluswamy, R., Mack, P. C., Houldsworth, J., Elkhouly, E., & Hirsch, F. R. (2021) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.02.002 · Cited by 96
Schram, A. M., Gandhi, L., Mita, M. M., Damstrup, L., Campana, F., Hidalgo, M., Grande, E., Hyman, D. M., & Heist, R. S. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0322-4 · Cited by 96
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
Conway, J. R. W., Herrmann, D., Evans, T. J., Morton, J. P., & Timpson, P. (2018) · Gut · doi:10.1136/gutjnl-2018-316822 · Cited by 104
“217 Similarly, the farnesyl transferase inhibitor, tipifarnib, did not prolong overall survival compared with gemcitabine alone in advanced PDAC.”
A small molecule inhibitor of Rheb selectively targets mTORC1 signaling
Mahoney, S. J., Narayan, S., Molz, L., Berstler, L. A., Kang, S. A., Vlasuk, G. P., & Saiah, E. (2018) · Nature Communications · doi:10.1038/s41467-018-03035-z · Cited by 88
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Chiorean, E. G., Chiaro, M. D., Tempero, M. A., Malafa, M. P., Benson, A. B., Cardin, D. B., Christensen, J. A., Chung, V. M., Czito, B. G., Dillhoff, M. E., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0034 · Cited by 122
“For example, the frequency of KRAS mutations seems to be comparable between ampullary cancer 44 , 45 and duodenal cancer 46 , 47 but is much lower in either cancer than in pancreatic cancer ( (cid:1) 30% – 40% vs (cid:1) 90% 48 ).”
BackgroundZhou, C., Fan, Z., Zhou, Z., Li, Y., Cui, R., Liu, C., Zhou, G., Diao, X., Jiang, H., Zheng, M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01774 · Cited by 94
Kerkour, A., Marquevielle, J., Иващенко, С. А., Yatsunyk, L. A., Mergny, J., & Salgado, G. F. J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.781906 · Cited by 107
“The very high affinity of the RAS GTP/GDP-binding site (picomolar range) (35, 36) has made it difficult to synthesize molecules that effectively compete with GTP at millimolar range inside cells to block KRAS activity (37).”
BackgroundLessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 94
Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis
Yin, C., Zhu, B., Zhang, T., Liu, T., Chen, S., Liu, Y., Li, X., Miao, X., Li, S., Mi, X., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.002 · Cited by 94
“However, unlike the well-defined inhibitors targeting the oncogenic BRAF mutation (Lavoie and Therrien, 2015), the development of NRAS-selective inhibitors has been unsuccessful in the past decades (Cox et al., 2014).”
Berr, A. L., Wiese, K. M., dos Santos, G., Koch, C. M., Anekalla, K. R., Kidd, M. E., Davis, J. M., Cheng, Y., Hu, Y., & Ridge, K. M. (2023) · Oncogene · doi:10.1038/s41388-023-02703-9 · Cited by 112
Issahaku, A. R., Mukelabai, N., Agoni, C., Rudrapal, M., Aldosari, S. M., Almalki, S. G., & Khan, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-22668-1 · Cited by 93
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer
Pecoraro, C., Faggion, B., Balboni, B., Carbone, D., Peters, G. J., Diana, P., Assaraf, Y. G., & Giovannetti, E. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100779 · Cited by 96
Advances in targeted degradation of endogenous proteins
Röth, S., Fulcher, L. J., & Sapkota, G. P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03112-6 · Cited by 92
A New View of Ras Isoforms in Cancers
Nussinov, R., Tsai, C.-J., Chakrabarti, M., & Jang, H. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1536 · Cited by 93
“These question the completeness of recorded statistics of isoforms in distinct cancer types (5, 6) and call for reassessment of procedures and protocols for tallying oncogenic mutations.”
Adhikari, H., & Counter, C. M. (2018) · Nature Communications · doi:10.1038/s41467-018-05692-6 · Cited by 91
Ferroptosis and its interaction with tumor immune microenvironment in liver cancer
Huang, Y., Wang, S., Ke, A., & Guo, K. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188848 · Cited by 124
Post-translational modifications and their implications in cancer
Dutta, H., & Jain, N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1240115 · Cited by 106
“The discovery that protein prenylation was required to maintain the malignant activity of oncogenic Ras GTPases evoked immense interest in this field, as Ras proteins have been known to drive more than 30% of human malignancies (98, 99).”
A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer
Yochum, Z. A., Cades, J., Mazzacurati, L., Neumann, N. M., Khetarpal, S. K., Chatterjee, S., Wang, H., Attar, M. A., Huang, E. H. ‐., Chatley, S. N. H., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0298 · Cited by 97
“In addition, patients with the most frequent molecular driver, mutant KRAS, lack effective targeted therapies (4).”
BackgroundDeactivation Pathway of Ras GTPase Underlies Conformational Substates as Targets for Drug Design
Lu, S., Ni, D., Wang, C., He, X., Lin, H., Wang, Z., & Zhang, J. (2019) · ACS Catalysis · doi:10.1021/acscatal.9b02556 · Cited by 93
KRAS oncogene repression in colon cancer cell lines by G-quadruplex binding indolo[3,2-c]quinolines
Lavrado, J., Brito, H., Borralho, P. M., Ohnmacht, S. A., Kim, N.-S., Leitão, C., Pisco, S., Gunaratnam, M., Rodrigues, C. M. P., Moreira, R., et al. (2015) · Scientific Reports · doi:10.1038/srep09696 · Cited by 92
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90
“Introduction RAS mutations occur in approximately 30% of human cancers, including the majority of pancreatic ductal adenocarcinoma (PDAC), half of colorectal cancers and a third of all lung cancers (Pylayeva-Gupta et al. 2011; Cox et al. 2014).”
BackgroundInfluentialRAS, wanted dead or alive: Advances in targeting RAS mutant cancers
Stalnecker, C. A., & Der, C. J. (2020) · Science Signaling · doi:10.1126/scisignal.aay6013 · Cited by 90
Self-citationDaraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
Wolpin, B. M., Park, W., Garrido-Laguna, I., Spira, A., Starodub, A., Sommerhalder, D., Punekar, S. R., Barve, M., Pelster, M., Herzberg, B., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2505783 · Cited by 90
Martín‐Gago, P., Fansa, E. K., Klein, C. H., Murarka, S., Janning, P., Schürmann, M., Metz, M., Ismail, S., Schultz‐Fademrecht, C., Baumann, M., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610957 · Cited by 88
López-Estévez, A. M., Lapuhs, P., Pineiro‐Alonso, L., & Alonso, M. J. (2023) · Advanced Materials · doi:10.1002/adma.202309355 · Cited by 108
Schott, C., Graab, U., Cuvelier, N., Hahn, H., & Fulda, S. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00131 · Cited by 90
“While RAS remains one of the most elusive genes to target directly, RAS mutant cells have been shown to depend on a number of oncogenic signaling pathways that arise as a means of adaptation to RASdriven intracellular stresses and represent unique vulnerabilities of mutant RAS cancers (18).”
BackgroundA Role for Mitochondrial Translation in Promotion of Viability in K-Ras Mutant Cells
Martin, T. D., Cook, D. R., Choi, M. Y., Li, M. Z., Haigis, K. M., & Elledge, S. J. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.061 · Cited by 89
“Molecules that block downstream Ras signaling, particularly mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) signaling, are also being investigated (Cox et al., 2014).”
BackgroundDirect inhibition of RAS: Quest for the Holy Grail?
Spencer-Smith, R., & O’Bryan, J. P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.005 · Cited by 86
“This failure has led to the perception of RAS as “undruggable”.(5) Recent advances in drug discovery techniques, high throughput”
BackgroundInfluentialKey Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies
Park, K., Veena, M. S., & Shin, D. S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.830208 · Cited by 97
Quantum Chemical-Based Protocol for the Rational Design of Covalent Inhibitors
Schirmeister, T., Kesselring, J., Jung, S., Schneider, T. H., Weickert, A., Becker, J., Lee, W., Bamberger, D., Wich, P. R., Distler, U., et al. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b03052 · Cited by 97
LINC00265 promotes colorectal tumorigenesis via ZMIZ2 and USP7-mediated stabilization of β-catenin
Zhu, Y., Gu, L., Lin, X., Cui, K., Liu, C., Lu, B., Zhou, F., Zhao, Q., Shen, H., & Li, Y. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0417-3 · Cited by 94
Selective and noncovalent targeting of RAS mutants for inhibition and degradation
Teng, K. W., Tsai, S. T., Hattori, T., Fedele, C., Koide, A., Yang, C., Hou, X., Zhang, Y., Neel, B. G., O’Bryan, J. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22969-5 · Cited by 87
“2 C-terminal to the VHL domain (1-213) with a SSSSG linker and N-terminal HA tag (YPYDVPDYA) following a published design34.”
BackgroundMethodActionable gene-based classification toward precision medicine in gastric cancer
Ichikawa, H., Nagahashi, M., Shimada, Y., Hanyu, T., Ishikawa, T., Kameyama, H., Kobayashi, T., Sakata, J., Yabusaki, H., Nakagawa, S., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0484-3 · Cited by 92
“KRAS itself is difficult to directly inhibit; therefore, inhibition of the downstream RAFMEK-ERK pathway is considered a promising treatment for KRAS-mutated tumors [31].”
BackgroundAtypical BRAF and NRAS Mutations in Mucosal Melanoma
Dumaz, N., Jouenne, F., Delyon, J., Mourah, S., Bensussan, A., & Lebbé, C. (2019) · Cancers · doi:10.3390/cancers11081133 · Cited by 97
“In physiological conditions, the MAPK pathway is activated by growth factors binding to their surface receptor tyrosine kinase (RTK), and the signal is transmitted through the small GTPase RAS [24].”
BackgroundThe Ras switch in structural and historical perspective
Gasper, R., & Wittinghofer, F. (2019) · Biological Chemistry · doi:10.1515/hsz-2019-0330 · Cited by 84
“This has been summarized in many reviews (see e.g. Cox et al., 2014; Spiegel et al., 2014; McCormick, 2015).”
MethodCDK4: a master regulator of the cell cycle and its role in cancer
Baker, S. J., Poulikakos, P. I., Irie, H. Y., Parekh, S. S., & Reddy, E. P. (2022) · Genes & Cancer · doi:10.18632/genesandcancer.221 · Cited by 90
Fang, Z., Marshall, C. B., Nishikawa, T., Gossert, A. D., Jansen, J. M., Jahnke, W., & Ikura, M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.07.009 · Cited by 86
Patel, D., Menon, D., Bernfeld, E., Mroz, V., Kalan, S., Loayza, D., & Foster, D. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.710145 · Cited by 86
“Thus, the observation that KRas-driven cancer cells arrest in S-phase in response to Q deprivation has important clinical implications, in that KRas itself has been considered undruggable (21).”
BackgroundLu, S., Banerjee, A., Jang, H., Zhang, J., Gaponenko, V., & Nussinov, R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.664755 · Cited by 85
“Oncogenic mutations, most commonly observed at amino acid residues Gly-12, Gly-13, and Gln-61, render Ras in a constitutively active GTPbound state (10), resulting in prolonged activation of downstream signaling, including MAPK (mitogen-activated protein kinase) and PI3K pathways (11, 12).”
BackgroundThe current clinical landscape of personalized cancer vaccines
Fritah, H., Rovelli, R., Chiang, C. L.-L., & Kandalaft, L. E. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102383 · Cited by 86
SIRT6 regulates Ras-related protein R-Ras2 by lysine defatty-acylation
Zhang, X., Spiegelman, N. A., Nelson, O. D., Jing, H., & Lin, H. (2017) · eLife · doi:10.7554/elife.25158 · Cited by 102
“For the Ras proteins that do not have palmitoylated cysteine (such as K-Ras4B), they are thought to use polybasic sequences for membrane targeting (Hancock, 2003; Cox et al., 2014).”
BackgroundPek, M., Yatim, S. M. J. M., Chen, Y., Li, J., Gong, M., Jiang, X., Zhang, F., Zheng, J., Wu, X., & Yu, Q. (2017) · Oncogene · doi:10.1038/onc.2017.120 · Cited by 86
Posttranslational Modifications of RAS Proteins
Ahearn, I., Zhou, M., & Philips, M. R. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031484 · Cited by 86
“Thus, the biochemical and cell biological properties of the products of RAS genes are a major focus for cancer biologists who hope to uncover vulnerabilities that can be exploited for drug discovery (Cox et al. 2014).”
BackgroundKras and tumor immunity: friend or foe?
Cullis, J., Das, S., & Bar-Sagi, D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031849 · Cited by 85
“An Inflamed Achilles Heel The disappointing outcome of the attempts to directly target oncogenic Ras (Cox et al. 2014) has generated an urgent need to develop alternative therapeutic strategies to treat mutant Rasdriven cancers.”
BackgroundGlutamine as an Essential Amino Acid for KRas-Driven Cancer Cells
Bernfeld, E., & Foster, D. A. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.03.003 · Cited by 85
Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment
Comen, E. A., Bowman, R. L., & Kleppe, M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00056 · Cited by 99
Drugging the Small GTPase Pathways in Cancer Treatment: Promises and Challenges
Prieto‐Domínguez, N., Parnell, C., & Teng, Y. (2019) · Cells · doi:10.3390/cells8030255 · Cited by 88
“Another possible approach consists in the correction of the profound imbalances that the mutations in KRas generate in the metabolism of carcinogenic cells [35,103].”
BackgroundMethodInfluentialTargeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 82
Predicting and characterizing a cancer dependency map of tumors with deep learning
Chiu, Y.-C., Zheng, S., Wang, L.-J., Iskra, B. S., Rao, M. K., Houghton, P. J., Huang, Y., & Chen, Y. (2021) · Science Advances · doi:10.1126/sciadv.abh1275 · Cited by 84
“Thus, targeting its SE interactors may be an effective alternative (42).”
BackgroundPhoto-induced radical thiol–ene chemistry: a versatile toolbox for peptide-based drug design
Ahangarpour, M., Kavianinia, I., Harris, P. W. R., & Brimble, M. A. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00354a · Cited by 92
Sogabe, S., Kamada, Y., Miwa, M., Niida, A., Sameshima, T., Kamaura, M., Yonemori, K., Sasaki, S., Sakamoto, J.-I., & Sakamoto, K. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00128 · Cited by 83
Del Re, M., Tiseo, M., Bordi, P., D’Incecco, A., Camerini, A., Petrini, I., Lucchesi, M., Inno, A., Spada, D., Vasile, E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.6957 · Cited by 83
“Targeting MUTKRAS proteins is still a challenge [34, 35].”
BackgroundMedicinal chemistry perspective of pyrido[2,3- d ]pyrimidines as anticancer agents
Kumar, A., Bhagat, K. K., Singh, A. K., Singh, H., Angre, T. D., Verma, A., Khalilullah, H., Jaremko, M., Emwas, A.-H. M., & Kumar, P. (2023) · RSC Advances · doi:10.1039/d3ra00056g · Cited by 97
“133,134 Ras protein mutations result in anomalies in the switch mechanism, a signi cant contributor to tumorigenesis.”
Nam, G.-H., Kwon, M., Jung, H., Ko, E., Kim, S. A., Choi, Y., Song, S. J., Kim, S., Lee, Y., Kim, G. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002474 · Cited by 82
Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Yamamoto, H., et al. (2025) · Cancers · doi:10.3390/cancers17030428 · Cited by 82
“For example, G12V is frequently identified in pancreatic ductal adenocarcinomas and is associated with aggressive disease biology [16,21].”
Protease-Resistant and Cell-Permeable Double-Stapled Peptides Targeting the Rab8a GTPase
Cromm, P. M., Spiegel, J., Küchler, P., Dietrich, L., Kriegesmann, J., Wendt, M., Goody, R. S., Waldmann, H., & Grossmann, T. N. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00386 · Cited by 79
Targeting the Ras palmitoylation/depalmitoylation cycle in cancer
Lin, D. T. S., Davis, N. G., & Conibear, E. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160303 · Cited by 90
Klomp, J. E., Klomp, J. A., & Der, C. J. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200507 · Cited by 91
Self-citationKazi, A., Xiang, S., Yang, H., Chen, L., Kennedy, P., Ayaz, M., Fletcher, S., Cummings, C., Lawrence, H. R., Beato, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3399 · Cited by 81
“However, targeting KRAS directly is challenging (8-12).”
BackgroundMolecular therapeutic targets in non-small cell lung cancer
Sankar, K. N., Gadgeel, S. M., & Qin, A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1787156 · Cited by 92
Sebastian, M., Eberhardt, W. E. E., Hoffknecht, P., Metzenmacher, M., Wehler, T., Kokowski, K., Alt, J., Schütte, W., Büttner, R., Heukamp, L. C., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.005 · Cited by 81
Anderson, G. R., Winter, P. S., Lin, K. H., Nussbaum, D. P., Cakir, M., Stein, E. M., Soderquist, R. S., Crawford, L., Leeds, J. C., Newcomb, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.006 · Cited by 80
“Finally, as a result of promising early findings, the strategy of targeting key RAS effector pathways has emerged as the focus of most translational research efforts (Cox et al., 2014).”
BackgroundInfluentialSelf-citationOncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80
Jones, G. G., del Río, I. B., Sari, S., Sekerim, A., Young, L. C., Hartig, N., Areso Zubiaur, I., El-Bahrawy, M. A., Hynds, R. E., Lei, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10367-x · Cited by 80
Lanfredini, S., Thapa, A., & O’Neill, E. E. (2019) · Biochemical Society Transactions · doi:10.1042/bst20170521 · Cited by 87
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 100
Nanodiscs: A Controlled Bilayer Surface for the Study of Membrane Proteins
McLean, M. A., Gregory, M. C., & Sligar, S. G. (2018) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-070816-033620 · Cited by 86
“Despite decades of research, pharmaceutical intervention in the Ras pathway has proven inefficacious, giving Ras the reputation of being undruggable (27).”
BackgroundLee, K., Fang, Z., Enomoto, M., Gasmi‐Seabrook, G., Zheng, L., Koide, S., Ikura, M., & Marshall, C. B. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202001758 · Cited by 79
Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients
Liu, J., Huang, X., Liu, H., Wei, C., Ru, H., Qin, H., Lai, H., Meng, Y., Wu, G., Xie, W., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02638-9 · Cited by 85
Coussens, N. P., Braisted, J. C., Peryea, T., Sittampalam, G. S., Simeonov, A. M., & Hall, M. D. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.013755 · Cited by 81
Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications
Shaban, N., Kamashev, D., Emelianova, A., & Buzdin, A. A. (2023) · Cells · doi:10.3390/cells13010047 · Cited by 94
“In addition, activating mutations of downstream genes of regulatory kinases involved in the Ras/MAPK signaling pathway, such as KRAS, NRAS, and BRAF, are exceptionally frequent and appear in more than 90% of pancreatic, ~32% of lung, and ~52% of colon cancers [64].”
BackgroundDirect Modulation of Small GTPase Activity and Function
Cromm, P. M., Spiegel, J., Grossmann, T. N., & Waldmann, H. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201504357 · Cited by 76
Cancer’s Achilles’ Heel: Apoptosis and Necroptosis to the Rescue
Dasgupta, A., Nomura, M., Shuck, R. L., & Yustein, J. T. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010023 · Cited by 86
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
Crook, Z. R., Sevilla, G. P., Friend, D., Brusniak, M.-Y., Bandaranayake, A. D., Clarke, M., Gewe, M., Mhyre, A. J., Baker, D., Strong, R. K., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02098-8 · Cited by 78
Santana-Codina, N., Chandhoke, A. S., Yu, Q., Małachowska, B., Kuljanin, M., Gikandi, A., Stańczak, M., Gableske, S., Jedrychowski, M. P., Scott, D. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.021 · Cited by 77
Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers
Untch, B. R., Anjos, V. D., García-Rendueles, M. E. R., Knauf, J. A., Krishnamoorthy, G. P., Saqcena, M., Bhanot, U. K., Socci, N. D., Ho, A. L., Ghossein, R. A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1925 · Cited by 83
“The relative rarity of HRAS mutations in cancers raised questions on whether it is a bona fide oncogenic driver and a legitimate therapeutic target (26), despite experimental evidence pointing to distinct transforming potency of mutant RAS isoforms in different cell lineages (27).”
BackgroundGarcia-Carbonero, N., Martínez‐Useros, J., Li, W., Orta, A., Pérez, N. T. I., Caramés, C., Hernández, T., Moreno, I., Serrano, G., & García‐Foncillas, J. (2020) · Cells · doi:10.3390/cells9010219 · Cited by 86
“KRAS mutations are found in codons 12 or 13 of exon 2 in the 90% of CRCs, especially in the phosphate-binding loop of the protein.”
Background
Metadata
- Authors
- Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Vanderbilt University (US)
- Dana-Farber Cancer Institute (US)
- National Cancer Institute (US)
- Corresponding author
- Der, Channing J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-10-17
- Volume
- 13
- Issue
- 11
- Pages
- 828-851
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4355017
- OpenAlex
- W2081990599
- Cited by
- 1,997
- References
- 231
- Citations by year
- 2026: 134 · 2025: 160 · 2024: 194 · 2023: 185 · 2022: 213 · 2021: 237 · 2020: 204 · 2019: 166 · 2018: 156 · 2017: 166 · 2016: 106 · 2015: 71 · 2014: 2
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (DP1OD006933, 5r01ca042978-30)
- U.S. Public Health Service (P50A095103-12)
- National Cancer Institute (P50CA127003, CA042978, R01CA175747, DP1CA174419, P50CA095103, CA175747, R01-CA042978, R21CA179193, RC2CA148375, CA179193, R01CA157490)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, RAS inhibitors, undruggable targets, synthetic lethality, RAS-mutant cancers, anticancer drug discovery, Ras signaling
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Signal Transduction, Oncogene Proteins, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.